Tenet Healthcare (NYSE:THC) Earns Buy Rating from Truist Financial

Posted by Brian Himes on Nov 3rd, 2026

Tenet Healthcare (NYSE:THC – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Truist Financial in a research report issued on Tuesday, Benzinga reports. They currently have a $305.00 price objective on the stock, up from their previous price objective of $290.00. Truist Financial‘s price objective would indicate a potential upside of 11.40% from the company’s previous close.

A number of other analysts have also issued reports on THC. Leerink Partners increased their price target on shares of Tenet Healthcare from $309.00 to $342.00 and gave the stock an “outperform” rating in a research report on Monday. Guggenheim lowered their price target on shares of Tenet Healthcare from $307.00 to $306.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler set a $308.00 price target on shares of Tenet Healthcare in a research note on Monday, July 27th. Raymond James Financial reiterated an “outperform” rating and set a $285.00 price objective on shares of Tenet Healthcare in a report on Friday, August 14th. Finally, UBS Group lifted their price objective on Tenet Healthcare from $288.00 to $308.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Eighteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $290.63.

View Our Latest Report on THC

Tenet Healthcare Stock Up 1.8%

Shares of THC traded up $4.89 during mid-day trading on Tuesday, reaching $273.79. The company’s stock had a trading volume of 369,430 shares, compared to its average volume of 1,116,537. Tenet Healthcare has a 1 year low of $157.58 and a 1 year high of $283.05. The company has a quick ratio of 1.35, a current ratio of 1.41 and a debt-to-equity ratio of 2.00. The company has a market cap of $22.04 billion, a price-to-earnings ratio of 7.95, a price-to-earnings-growth ratio of 1.02 and a beta of 1.20. The business has a fifty day moving average of $264.61 and a 200 day moving average of $220.69.

Tenet Healthcare (NYSE:THC – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $4.68 by $1.96. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%. The firm had revenue of $6.28 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same period in the previous year, the firm earned $3.70 earnings per share. Tenet Healthcare’s quarterly revenue was up 6.5% on a year-over-year basis. As a group, analysts forecast that Tenet Healthcare will post 21.98 earnings per share for the current fiscal year.

Insider Transactions at Tenet Healthcare

In related news, Director J. Robert Kerrey sold 12,010 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $263.72, for a total value of $3,167,277.20. Following the transaction, the director directly owned 4,794 shares of the company’s stock, valued at approximately $1,264,273.68. This trade represents a 71.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saumya Sutaria sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $278.71, for a total value of $13,935,500.00. Following the completion of the sale, the chief executive officer owned 483,564 shares of the company’s stock, valued at approximately $134,774,122.44. This trade represents a 9.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 106,484 shares of company stock valued at $28,898,063 in the last three months. 0.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC lifted its holdings in shares of Tenet Healthcare by 1.7% during the third quarter. Ashton Thomas Private Wealth LLC now owns 2,468 shares of the company’s stock valued at $631,000 after acquiring an additional 42 shares during the period. Heritage Family Offices LLP acquired a new position in Tenet Healthcare during the 3rd quarter worth about $98,000. Syverson Strege & Co bought a new stake in shares of Tenet Healthcare during the third quarter valued at approximately $203,000. Kestra Advisory Services LLC increased its stake in shares of Tenet Healthcare by 211.3% in the 3rd quarter. Kestra Advisory Services LLC now owns 18,898 shares of the company’s stock valued at $4,830,000 after buying an additional 12,827 shares during the period. Finally, Commonwealth Equity Services LLC raised its holdings in Tenet Healthcare by 13.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 5,232 shares of the company’s stock worth $1,337,000 after purchasing an additional 626 shares during the last quarter. Institutional investors own 95.44% of the company’s stock.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

Positive Sentiment: KeyCorp raised its price target from $270 to $300 and maintained an “overweight” rating, implying approximately 9.9% potential upside from the referenced share price. KeyCorp recommendations
Positive Sentiment: Leerink Partners increased its target from $309 to $342 and assigned an “outperform” rating, the most optimistic target among the latest analyst revisions, with roughly 25.3% implied upside. Leerink Partners recommendations
Positive Sentiment: Royal Bank of Canada raised its target from $283 to $304 and kept an “outperform” rating, reflecting expectations for further gains. RBC recommendations
Positive Sentiment: Wells Fargo lifted its target from $281 to $321 and maintained an “overweight” rating, citing a favorable outlook for Tenet’s earnings trajectory. Wells Fargo recommendations
Positive Sentiment: Tenet reportedly raised its 2026 EBITDA outlook following third-quarter results, while its earnings call pointed to stronger growth ahead. The improved outlook supports the recent upward revisions in analyst targets. Tenet Healthcare EBITDA outlook
Negative Sentiment: Guggenheim trimmed its price target for Tenet Healthcare, providing a counterpoint to the broader wave of bullish revisions and signaling that some analysts remain cautious about valuation or execution risks. Guggenheim price target update

Tenet Healthcare Company Profile

(Get Free Report)

Tenet Healthcare Corp. (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, Texas. Through its hospital operations and outpatient platforms, the company provides a range of medical services to patients across the United States.

Tenet operates acute care and specialty hospitals, ambulatory surgery centers, imaging facilities and other outpatient care sites. Its United Surgical Partners International subsidiary is a major provider of ambulatory surgery services and partners with physicians and health systems.